Additional key phrases: xanthoma; monoclonal gammopathy; lipid fractionation; ultracentrifugation Malignant paraproteinaemia is most often associated with either hypolipidaemia or normal serum lipid concentrations but may, occasionally, be associated with hyperlipidaemia.' It has been suggested that hyperlipidaemia results from binding of the paraprotein to serum lipoproteins or from inhibition of lipoprotein lipase, thereby preventing further metabolism of serum lipoproteins. ? We report an unusual case of hyperlipidaemia in association with benign paraproteinaemia where the serum lipid concentrations reflected that of the paraprotein.
CASE HISTORY
DG, a 51-year-old woman, presented in 1981 with a 5 year history of extensive periorbital xanthelasma and yellow-brown nodules over her antecubital fossae, axillae, temples, neck and knees. Her past medical history included an appendicectomy in 1956 and a right oophorectomy in 1966 for a benign ovarian cyst. One maternal uncle had died aged 40 with a myocardial infarction, but her family tree was otherwise free of premature vascular disease. On examination, her height was 155cm, weight 54·8 kg, blood pressure 140/80. There were small, easily palpable lymph nodes in both groins.
Immunofixation demonstrated the presence of an IgG-K (immunoglobulin G) paraprotein present at 16g/L. Bence Jones protein was not detected. Bone marrow biopsy was normal. Biopsy of an antecubital fossa confirmed the yellow-brown eruptions as xanthomata-immunoglobulin deposition was not found in these lesions. A diagnosis of benign IgG-K paraproteinaemia was made and the serum paraprotein concentration was assessed at regular intervals thereafter. Although her clinical picture did not change, suspicions about her paraproteinaemia plus skin manifestations resulted in a course of melphalan 10 mg plus prednisolone 20 mg at I monthly intervals for 16 months in 1984. This was stopped when it became clear that the paraprotein concentration was unaffected and when dysplastic changes (thought to be related to the chemotherapy) were found on repeat bone marrow examination. Marginal thrombocytopenia (platelets about 120 x 10 9/L) has been present since January 1995.
DG has been treated with a variety of lipidlowering medication including: (i) bezafibrate with and without cholestyramine; (ii) probucol with and without cholestyramine; and (iii) simvastatin. None of these drugs has been shown to improve her serum lipid profile. Indeed, from January 1993, her serum lipid concentrations rose progressively, as did her paraprotein concentration ( Fig. I) . The lipid concentrations clearly mirror the paraprotein concentrations except for the period during chemotherapy when her serum triglyceride concentration rose to about 5·5 mmol/L, presumably as a consequence of oral prednisolone.
We decided to investigate the apparent association between the serum concentrations of the paraprotein and lipids. The patient stopped all lipid-lowering medication for 2 months before investigations in February 1996.
Serum was collected and subjected to lipid ultracentrifugation.! We found, however, that over 85% of the serum paraprotein and lipid were deposited in the first pellet which is normally composed of traces of globulin and albumin. Attempts to prevent co-sedimentation by changing the composition of the centrifugation medium were unsuccessful. We have carried out ultracentrifugation of serum from other patients with a combination of paraproteinaemia and hyperlipidaemia and have not found any sera in which the paraprotein co-sediments with lipids. We assayed low-density lipoprotein (LDL) by direct immunoseparation (Sigma Diagnostics, Poole, UK) and high-density lipoprotein (HDL) by precipitation (Reference Diagnostics Inc, Arlington, VA, USA) in order to avoid centrifugation steps. Apolipoproteins AI, A2 and B were assayed by immunoturbidimetry (Boehringer-Mannheim, Mannheim, Germany). The IgG-K paraprotein did not block immunoseparation of LDL from the other lipoprotein fractions and did not appear to interfere with immunoturbidimetric assay of the apolipoproteins or with HDL estimation by chemical precipitation of the other lipoproteins, though we cannot exclude subtle interference. Serum protein electrophoresis, lipoprotein electrophoresis and immunofixation (Helena Laboratories, Gateshead, UK) of DG's serum confirmed the paraprotein to be IgG-K (quantified by scanning densitometry) and confirmed the presence of HDL and LDL particles, but we could not demonstrate co-migration of the paraprotein with either of these particles. Moreover, immunofixation of the serum with antibodies to apolipoproteins A I, A2 and B demonstrated that these particles did not comigrate with the paraprotein.
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Ann Clin Biochem 1997: 34 Electron microscopy of the first pellet confirmed the presence of particles predominantly of the size of LDL particles but did not demonstrate inter-binding of these particles.
We have not, therefore, been able to demonstrate specific binding between the paraprotein and lipoprotein particles. Although we cannot exclude the possibility that the association is a laboratory artefact, the clear correlation between lipid and paraprotein concentrations over time demonstrated in Fig. I would suggest otherwise and might be consistent with a nonspecific hydrophobic association.
We were unwilling to measure DG's pre-and post-heparin serum lipoprotein lipase activity in view of her low platelet count.
DISCUSSION
Planar xanthomata have been described in association with hypothyroidism, congenital deficiencies of apolipoprotein A, primary biliary cirrhosis and malignant paraproteinaernia." The association between primary biliary cirrhosis and hyperlipidaemia and xanthomata is perhaps particularly relevant-the physical properties of patients' sera in this condition are thought to favour retention of lipid-rich particles through an hydrophobic interaction." It is possible that a similar mechanism is operating in the serum of DG in whom the distribution and appearance of the planar xanthomata are remarkably similar to that found in patients with primary biliary cirrhosis.
Apart from the cosmetic effect of the planar xanthomata, DG has remained remarkably symptom-free throughout her association with the lipid clinic. The xanthomata have remained stable over the last 10 years and she is able to mask the facial eruptions with make-up. She no longer takes any lipid-lowering medication in view of the absence of signs or symptoms of vascular disease, and because all agents which were tried had no effect on her serum lipid concentrations. Atherosclerosis has been reported in association with paraprotein-related hyperlipidaemia' but it is not certain if this is a real association.?
The case of DG is an example of an association between monoclonal gammopathy and xanthoma which illustrates the following learning points:
(a) planar xanthoma in an adult should stimulate screening for a serum paraprotein (b) xanthoma may occur in paraproteinaemia even with relatively normal lipid levels (as at the time of presentation of this case) (c) hyperlipidaemia associated with a paraprotein may respond poorly to lipid lowering medication (d) hyperlipidaemia associated with a paraprotein need not be associated with progression of vascular disease.
